Renata Pasqualini

Mbrace Therapeutics, Inc. is an American company that specializes in antibody discovery methodology. The company's approach, called SPARTA, overcomes several challenges to generate human antibodies that can be quickly translated into clinical applications. Mbrace Therapeutics was founded by Renata Pasqualini, Isan Chen, and Wadih Arap, with Isan Chen serving as the CEO since incorporation.

Mercator Therapeutics develops novel cancer drugs. It is the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs. The company was founded by Wadih Arap, Renata Pasqualini, Roy Lobb, Mark Leuchtenberger, and Christopher Guiffre in 2009 is headquartered in Wellesley, MA.

Mbrace Therapeutics, Inc. is an American company that specializes in antibody discovery methodology. The company's approach, called SPARTA, overcomes several challenges to generate human antibodies that can be quickly translated into clinical applications. Mbrace Therapeutics was founded by Renata Pasqualini, Isan Chen, and Wadih Arap, with Isan Chen serving as the CEO since incorporation.

PhageNova Bio, Inc. is a biotechnology company that is developing a modular, bacteriophage-based platform for targeted gene expression in cancer, vaccination, and molecular imaging. PhageNova Bio is based in Scarsdale, NY. The company's lead cancer construct is designed to selectively target tumor-associated blood vessels and tumor cells, resulting in the expression of TNF-?, an anti-tumor agent, specifically and exclusively in tumors. The company has extensively validated tumor targeting and selective gene expression capabilities, and therapeutic efficacy was observed in the absence of dose-limiting toxicity in multiple species and several tumor models. The company was founded by Renata Pasqualini, Wadih Arap, Steven K. Libutti, Juri G. Gelovani, and the CEO is Jason A. Rifkin.

PhageNova Bio, Inc. is a biotechnology company that is developing a modular, bacteriophage-based platform for targeted gene expression in cancer, vaccination, and molecular imaging. PhageNova Bio is based in Scarsdale, NY. The company's lead cancer construct is designed to selectively target tumor-associated blood vessels and tumor cells, resulting in the expression of TNF-?, an anti-tumor agent, specifically and exclusively in tumors. The company has extensively validated tumor targeting and selective gene expression capabilities, and therapeutic efficacy was observed in the absence of dose-limiting toxicity in multiple species and several tumor models. The company was founded by Renata Pasqualini, Wadih Arap, Steven K. Libutti, Juri G. Gelovani, and the CEO is Jason A. Rifkin.

PhageNova Bio, Inc. is a biotechnology company that is developing a modular, bacteriophage-based platform for targeted gene expression in cancer, vaccination, and molecular imaging. PhageNova Bio is based in Scarsdale, NY. The company's lead cancer construct is designed to selectively target tumor-associated blood vessels and tumor cells, resulting in the expression of TNF-?, an anti-tumor agent, specifically and exclusively in tumors. The company has extensively validated tumor targeting and selective gene expression capabilities, and therapeutic efficacy was observed in the absence of dose-limiting toxicity in multiple species and several tumor models. The company was founded by Renata Pasqualini, Wadih Arap, Steven K. Libutti, Juri G. Gelovani, and the CEO is Jason A. Rifkin.